Gemcitabine for Marginal Zone Lymphoma

This study has been terminated.
(poor accrual and response less than expected on interim analysis)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Cheolwon Suh, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00337259
First received: June 14, 2006
Last updated: February 13, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2009
  Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)